Non-opioid Pain Patch Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Non-opioid Pain Patch market is expected to register a CAGR of 3.0% during the forecast period, 2022-2027.

The COVID-19 pandemic has impacted the healthcare systems across the world. The health agencies are engaged in containing coronavirus transmission through lockdown norms and have deferred most of the elective and non-urgent surgeries globally. According to the study titled "Pain Management During the COVID-19 Pandemic" published in the Pain and therapy in December 2020, Opioid overuse, surgical overuse, and a failure to provide education or advice are examples of general, pre-existing problems that have been exacerbated as a result of the COVID-19 pandemic. As a result, the use of non-opioid pain relievers has increased. For COVID-19 patients, newly prescribed oral NSAIDs may only be used intermittently for a very short period of time. Thus, the Non-Opioid pain patch market significantly impacted COVID-19.

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The global incidence of cancer is high. As per the GLOBOCAN 2020 report, the incidence of new cancer cases accounted for 19,292,789 globally and 9,958,133 cancer-related deaths in 2020. Thus, the high incidence of cancer may increased in the cancer associated pain, which may increase the demand for cancer pain management drugs and devices, thereby boost the market.

Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting among other ways, an underlying disease like pancreatitis, spine disease, arthritis, and autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. As per, Center for Diseases Control and Prevention in May 2020, around 43% of the population suffer from pain on some days and around 20% of the population suffer from pain every day or on most days. There are numerous risk factors for chronic pain. Non-opioid patches are more preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches and also the drugs is released over a long period of time, therefore, helping in managing the pain for a longer duration and considered as a valuable driver for the Non-opioid Pain Patch market.

Meanwhile, a few other players are conducting extensive R&D by collaborating with educational institutions to introduce new non-narcotic pain patches. For Instance, in July 2020, The United States Food and Drug Administration approved a 8% capsaicin patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. The patch is a non-opioid, non-systemic, and topical pain treatment that is the only one on the market that delivers prescription strength capsaicin directly into the patient's skin.

However, availability of alternative treatments and low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of non-opioid pain patch market.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Lidocaine patches are considered the most commonly available patch for the treatment of chronic and acute pain. The factors such as the rise in prevalence of pain and product launch by the key market players boost the segment growth.

According to the Centers for Disease Control and Prevention (CDC) November 2020, in 2019 overall prevalence of chronic pain was 20.4 %, with 7.4 % having high-impact chronic pain (or 36.4 percent of adults who had chronic pain). Women (21.7%), non-Hispanic white adults (23.6%), and those aged 65 and up had the highest rates of chronic pain (30.8 percent ), and the percentage of adults experiencing this type of pain increased as their place of residence became more rural. Thus, rising chronic pain cases and the widespread availability of lidocaine pain relief patches are expected to drive the segment.

Increasing product launches by key market players are anticipated to boost the market. For instance, in August 2020, Amneal Pharmaceuticals, Inc. received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for treatment of post-herpetic neuralgia.

Furthermore, the increasing burden of diseases, along with safety profile and efficacy associated with lidocaine patches are expected to drive the growth of the Non-opioid Pain Patch market during the forecast period.

North America is Expected to Dominate the Non-opioid Pain Patch Market Over the Forecast Period

North America is expected to retain its dominance in this market due to the rising in prevalence of pain in the region as well as product launches by the key market players in the region expected to boost the market growth over the forecast period.

Chronic pain is one of the primary factors responsible for the growth of the market. According to the study titled " Prevalence of Pain Management Techniques Among Adults With Chronic Pain in the United States, 2019" published in the JAMA Network in February 2022, 2019, it is estimated that one in every five adults in the United States suffered from chronic pain. 1 in 14 adults experienced severe chronic pain. In addition, the countries in North America are increasingly facing scrutiny on the opioid crisis issue, from the government authorities, which in turn are expected to benefit from the rise of non-opioid alternatives. Thus, the rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

In addition, product launches by the key market players are anticipated to boost the market over the forecast period. For instance, in July 2020, The United States Food and Drug Administration approved an 8% capsaicin patch (Qutenza, Grünenthal and Averitas Pharma) for the treatment of adults with neuropathic pain associated with diabetic peripheral neuropathy of the feet.

Additionally in September 2021, Vizuri Health Sciences Consumer Healthcare, Inc. entered into a partnership with world renowned surfer, lifestyle coach and mother Bethany Hamilton a partner with the company for the launch of its PainBloc24 ProWomen Pain Relief Patch.

Thus, all aforementioned factors anticipated to boost the market over the forecast period.

Competitive Landscape

The market is highly fragmented because numerous companies are working to help a large global population suffering from chronic pain. To increase consumer base and product penetration, various market players use a wide range of technologies to develop products that facilitate effective and prolonged drug release. Furthermore, the market is highly competitive, with fierce competition between existing players and new entrants. The global players in the non-opioid pain patch market are - Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.